Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?

The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.